MXPA04012272A - Nuevos derivados de quinuclidina y composiciones medicinales que contienen los mismos. - Google Patents
Nuevos derivados de quinuclidina y composiciones medicinales que contienen los mismos.Info
- Publication number
- MXPA04012272A MXPA04012272A MXPA04012272A MXPA04012272A MXPA04012272A MX PA04012272 A MXPA04012272 A MX PA04012272A MX PA04012272 A MXPA04012272 A MX PA04012272A MX PA04012272 A MXPA04012272 A MX PA04012272A MX PA04012272 A MXPA04012272 A MX PA04012272A
- Authority
- MX
- Mexico
- Prior art keywords
- ylmethyl
- azoniabicyclo
- octane
- compound
- optionally substituted
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 16
- 150000008584 quinuclidines Chemical class 0.000 title 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 claims abstract description 12
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 claims abstract description 12
- 150000003839 salts Chemical class 0.000 claims abstract description 11
- 239000005557 antagonist Substances 0.000 claims abstract description 4
- 150000003242 quaternary ammonium salts Chemical class 0.000 claims abstract description 4
- -1 furan-2-ylmethyl Chemical group 0.000 claims description 440
- 150000001875 compounds Chemical class 0.000 claims description 281
- 150000002148 esters Chemical class 0.000 claims description 65
- 239000002253 acid Substances 0.000 claims description 45
- 125000001424 substituent group Chemical group 0.000 claims description 42
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 39
- 239000000203 mixture Substances 0.000 claims description 38
- 125000000217 alkyl group Chemical group 0.000 claims description 29
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 29
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 27
- 125000004122 cyclic group Chemical group 0.000 claims description 26
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims description 24
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 21
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 21
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 19
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 claims description 16
- CNWBYOPCIWGBPG-AMSMYJGSSA-N [(3r)-1-(2-phenoxyethyl)-1-azoniabicyclo[2.2.2]octan-3-yl] n-(3-fluorophenyl)-n-[(3,4,5-trifluorophenyl)methyl]carbamate Chemical compound FC1=CC=CC(N(CC=2C=C(F)C(F)=C(F)C=2)C(=O)O[C@@H]2C3CC[N+](CC3)(CCOC=3C=CC=CC=3)C2)=C1 CNWBYOPCIWGBPG-AMSMYJGSSA-N 0.000 claims description 14
- 125000003545 alkoxy group Chemical group 0.000 claims description 13
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 13
- 208000023504 respiratory system disease Diseases 0.000 claims description 13
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 229910052736 halogen Inorganic materials 0.000 claims description 12
- 150000002367 halogens Chemical class 0.000 claims description 12
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 11
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 11
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 10
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims description 10
- 125000003342 alkenyl group Chemical group 0.000 claims description 10
- 125000004432 carbon atom Chemical group C* 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 10
- 229910052731 fluorine Inorganic materials 0.000 claims description 10
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 10
- 229920006395 saturated elastomer Polymers 0.000 claims description 10
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical group NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 claims description 9
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 claims description 9
- 125000004414 alkyl thio group Chemical group 0.000 claims description 9
- 125000000304 alkynyl group Chemical group 0.000 claims description 9
- 125000000623 heterocyclic group Chemical group 0.000 claims description 9
- 208000014001 urinary system disease Diseases 0.000 claims description 9
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims description 8
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 8
- 150000001450 anions Chemical class 0.000 claims description 8
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 239000011737 fluorine Substances 0.000 claims description 8
- 125000001153 fluoro group Chemical group F* 0.000 claims description 8
- 125000001072 heteroaryl group Chemical group 0.000 claims description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 8
- YEESKJGWJFYOOK-IJHYULJSSA-N leukotriene D4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@H](N)C(=O)NCC(O)=O YEESKJGWJFYOOK-IJHYULJSSA-N 0.000 claims description 8
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims description 7
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 7
- 229910052794 bromium Inorganic materials 0.000 claims description 7
- 239000000460 chlorine Substances 0.000 claims description 7
- 229910052801 chlorine Inorganic materials 0.000 claims description 7
- 125000004076 pyridyl group Chemical group 0.000 claims description 7
- 230000000241 respiratory effect Effects 0.000 claims description 7
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 7
- 125000006284 3-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(F)=C1[H])C([H])([H])* 0.000 claims description 6
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims description 6
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 6
- 125000004429 atom Chemical group 0.000 claims description 6
- 125000004981 cycloalkylmethyl group Chemical group 0.000 claims description 6
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 6
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims description 5
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 5
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 5
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims description 5
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 5
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 5
- 125000005843 halogen group Chemical group 0.000 claims description 5
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims description 5
- VQKFNUFAXTZWDK-UHFFFAOYSA-N 2-Methylfuran Chemical compound CC1=CC=CO1 VQKFNUFAXTZWDK-UHFFFAOYSA-N 0.000 claims description 4
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims description 4
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 claims description 4
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 4
- 230000008485 antagonism Effects 0.000 claims description 4
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 claims description 4
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 claims description 4
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims description 4
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 4
- 230000006872 improvement Effects 0.000 claims description 4
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims description 4
- 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 claims description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
- QDKWLJJOYIFEBS-UHFFFAOYSA-N 1-fluoro-4-$l^{1}-oxidanylbenzene Chemical group [O]C1=CC=C(F)C=C1 QDKWLJJOYIFEBS-UHFFFAOYSA-N 0.000 claims description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 3
- 239000000043 antiallergic agent Substances 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 3
- AAPAVYWERMFERN-UHFFFAOYSA-N ethyl(phenyl)carbamic acid Chemical compound CCN(C(O)=O)C1=CC=CC=C1 AAPAVYWERMFERN-UHFFFAOYSA-N 0.000 claims description 3
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 claims description 3
- 125000001624 naphthyl group Chemical group 0.000 claims description 3
- 150000003431 steroids Chemical class 0.000 claims description 3
- CZMKHDWWENJEBB-UHFFFAOYSA-N (2,5-dimethylfuran-3-yl)methyl-[(2-fluoro-4-methoxyphenyl)methyl]carbamic acid Chemical compound FC1=CC(OC)=CC=C1CN(C(O)=O)CC1=C(C)OC(C)=C1 CZMKHDWWENJEBB-UHFFFAOYSA-N 0.000 claims description 2
- MHHNSASWUJLGQC-UHFFFAOYSA-N (4,5-dimethylfuran-2-yl)methyl-[(5-methylfuran-2-yl)methyl]carbamic acid Chemical compound O1C(C)=CC=C1CN(C(O)=O)CC1=CC(C)=C(C)O1 MHHNSASWUJLGQC-UHFFFAOYSA-N 0.000 claims description 2
- 125000004208 3-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C([H])C(*)=C1[H] 0.000 claims description 2
- 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 claims description 2
- VFCSBXIKJWAJAR-PGSWAALUSA-N [(3r)-1-(3-phenylpropyl)-1-azoniabicyclo[2.2.2]octan-3-yl] n-(3-fluorophenyl)-n-[(3-fluorophenyl)methyl]carbamate Chemical compound FC1=CC=CC(CN(C(=O)O[C@@H]2C3CC[N+](CC3)(CCCC=3C=CC=CC=3)C2)C=2C=C(F)C=CC=2)=C1 VFCSBXIKJWAJAR-PGSWAALUSA-N 0.000 claims description 2
- QFQQEWMLRDCTMK-YCQMHXFUSA-N [(3r)-1-(3-phenylpropyl)-1-azoniabicyclo[2.2.2]octan-3-yl] n-[(5-ethylthiophen-2-yl)methyl]-n-[(3-methylthiophen-2-yl)methyl]carbamate Chemical compound S1C(CC)=CC=C1CN(C(=O)O[C@@H]1C2CC[N+](CC2)(CCCC=2C=CC=CC=2)C1)CC1=C(C)C=CS1 QFQQEWMLRDCTMK-YCQMHXFUSA-N 0.000 claims description 2
- ZAPBKMWEEFIAGB-WTRWISCVSA-M [(3r)-1-heptyl-1-azoniabicyclo[2.2.2]octan-3-yl] n-butyl-n-(2,5-difluorophenyl)carbamate;2,2,2-trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F.O([C@@H]1C2CC[N+](CC2)(C1)CCCCCCC)C(=O)N(CCCC)C1=CC(F)=CC=C1F ZAPBKMWEEFIAGB-WTRWISCVSA-M 0.000 claims description 2
- CEGCCCRGQJUBCW-BAMNPNLJSA-N [(3r)-1-methyl-1-azoniabicyclo[2.2.2]octan-3-yl] n-(cyclohexylmethyl)-n-(2-fluorophenyl)carbamate Chemical compound O([C@@H]1C2CC[N+](CC2)(C1)C)C(=O)N(C=1C(=CC=CC=1)F)CC1CCCCC1 CEGCCCRGQJUBCW-BAMNPNLJSA-N 0.000 claims description 2
- ICYPDFVERJXLOW-RBPPWHDLSA-M [(3r)-1-methyl-1-azoniabicyclo[2.2.2]octan-3-yl] n-benzyl-n-(2-methylphenyl)carbamate;iodide Chemical compound [I-].CC1=CC=CC=C1N(C(=O)O[C@@H]1C2CC[N+](CC2)(C)C1)CC1=CC=CC=C1 ICYPDFVERJXLOW-RBPPWHDLSA-M 0.000 claims description 2
- DXNQLZJOTVNBOZ-UHFFFAOYSA-N [O]C(=O)Nc1ccccc1 Chemical group [O]C(=O)Nc1ccccc1 DXNQLZJOTVNBOZ-UHFFFAOYSA-N 0.000 claims description 2
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 claims description 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims description 2
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 claims description 2
- 125000003518 norbornenyl group Chemical group C12(C=CC(CC1)C2)* 0.000 claims description 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 2
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims description 2
- JOYRKODLDBILNP-UHFFFAOYSA-N urethane group Chemical group NC(=O)OCC JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 claims description 2
- TVSLNRQODQRVJZ-UHFFFAOYSA-N 2-(3,4,5-trifluorophenyl)acetonitrile Chemical group FC1=CC(CC#N)=CC(F)=C1F TVSLNRQODQRVJZ-UHFFFAOYSA-N 0.000 claims 2
- 208000012931 Urologic disease Diseases 0.000 claims 2
- 208000010643 digestive system disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 2
- 230000001575 pathological effect Effects 0.000 claims 2
- UWFYPZAJXOAIHQ-UHFFFAOYSA-N (5-ethylthiophen-2-yl)methyl-[(3-methylthiophen-2-yl)methyl]carbamic acid Chemical compound S1C(CC)=CC=C1CN(C(O)=O)CC1=C(C)C=CS1 UWFYPZAJXOAIHQ-UHFFFAOYSA-N 0.000 claims 1
- BZYUMXXOAYSFOW-UHFFFAOYSA-N 2,3-dimethylthiophene Chemical compound CC=1C=CSC=1C BZYUMXXOAYSFOW-UHFFFAOYSA-N 0.000 claims 1
- KOVBLMNQGVQJHN-IBGZPJMESA-N [(3r)-1-azabicyclo[2.2.2]octan-3-yl] n-(4-fluoro-2-methylphenyl)-n-[(3-methylthiophen-2-yl)methyl]carbamate Chemical compound C1=CSC(CN(C(=O)O[C@@H]2C3CCN(CC3)C2)C=2C(=CC(F)=CC=2)C)=C1C KOVBLMNQGVQJHN-IBGZPJMESA-N 0.000 claims 1
- IUIUVONRBVKRHR-FQEVSTJZSA-N [(3r)-1-azabicyclo[2.2.2]octan-3-yl] n-[2-(4-fluorophenyl)ethyl]-n-[(3-methylthiophen-2-yl)methyl]carbamate Chemical compound C1=CSC(CN(CCC=2C=CC(F)=CC=2)C(=O)O[C@@H]2C3CCN(CC3)C2)=C1C IUIUVONRBVKRHR-FQEVSTJZSA-N 0.000 claims 1
- XAKKKEVZQFSYKZ-QBJDRERVSA-M [(3r)-1-methyl-1-azoniabicyclo[2.2.2]octan-3-yl] n-[(4-fluorophenyl)methyl]-n-(3-methylphenyl)carbamate;iodide Chemical compound [I-].CC1=CC=CC(N(CC=2C=CC(F)=CC=2)C(=O)O[C@@H]2C3CC[N+](CC3)(C)C2)=C1 XAKKKEVZQFSYKZ-QBJDRERVSA-M 0.000 claims 1
- ZPDVAXBLZFPQPQ-QNHHWSGXSA-M [(3r)-1-methyl-1-azoniabicyclo[2.2.2]octan-3-yl] n-benzyl-n-(2-fluorophenyl)carbamate;iodide Chemical compound [I-].O([C@@H]1C2CC[N+](CC2)(C1)C)C(=O)N(C=1C(=CC=CC=1)F)CC1=CC=CC=C1 ZPDVAXBLZFPQPQ-QNHHWSGXSA-M 0.000 claims 1
- 229940124748 beta 2 agonist Drugs 0.000 claims 1
- 125000001207 fluorophenyl group Chemical group 0.000 claims 1
- NCIKRCLQGDFITI-UHFFFAOYSA-N furan-3-ylmethyl-[[5-methyl-2-(trifluoromethyl)furan-3-yl]methyl]carbamic acid Chemical compound O1C(C)=CC(CN(CC2=COC=C2)C(O)=O)=C1C(F)(F)F NCIKRCLQGDFITI-UHFFFAOYSA-N 0.000 claims 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims 1
- SBYHFKPVCBCYGV-UHFFFAOYSA-N quinuclidine Chemical compound C1CC2CCN1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-N 0.000 claims 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims 1
- NVPDHMOHVWSMJD-UHFFFAOYSA-N thiophen-3-ylmethyl-[(2,4,5-trifluorophenyl)methyl]carbamic acid Chemical compound C=1C(F)=C(F)C=C(F)C=1CN(C(=O)O)CC=1C=CSC=1 NVPDHMOHVWSMJD-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 205
- 238000002360 preparation method Methods 0.000 abstract description 41
- 230000008569 process Effects 0.000 abstract description 6
- 238000002560 therapeutic procedure Methods 0.000 abstract description 3
- 150000004657 carbamic acid derivatives Chemical class 0.000 abstract description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 102
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 40
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 36
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 32
- KAEPUDLIBVYOEJ-XAEROCQYSA-M [(3r)-1-(2-phenoxyethyl)-1-azoniabicyclo[2.2.2]octan-3-yl] n-(4-fluoro-2-methylphenyl)-n-[(3-methylthiophen-2-yl)methyl]carbamate;2,2,2-trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F.C1=CSC(CN(C(=O)O[C@@H]2C3CC[N+](CC3)(CCOC=3C=CC=CC=3)C2)C=2C(=CC(F)=CC=2)C)=C1C KAEPUDLIBVYOEJ-XAEROCQYSA-M 0.000 description 32
- 239000000243 solution Substances 0.000 description 28
- 238000005481 NMR spectroscopy Methods 0.000 description 26
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 23
- 239000003921 oil Substances 0.000 description 22
- 239000000047 product Substances 0.000 description 21
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 239000000725 suspension Substances 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 13
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 11
- 239000011734 sodium Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 10
- 229910052708 sodium Inorganic materials 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- 101150041968 CDC13 gene Proteins 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 9
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- MMGCSKMTMZKVAU-UHFFFAOYSA-N (3-fluorophenyl)-[(3,4,5-trifluorophenyl)methyl]carbamic acid Chemical compound C=1C=CC(F)=CC=1N(C(=O)O)CC1=CC(F)=C(F)C(F)=C1 MMGCSKMTMZKVAU-UHFFFAOYSA-N 0.000 description 7
- WKFZHVFBHYHYAK-UHFFFAOYSA-N benzyl(phenyl)carbamic acid Chemical compound C=1C=CC=CC=1N(C(=O)O)CC1=CC=CC=C1 WKFZHVFBHYHYAK-UHFFFAOYSA-N 0.000 description 7
- 235000019441 ethanol Nutrition 0.000 description 7
- 239000012074 organic phase Substances 0.000 description 7
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 150000001412 amines Chemical class 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- DJLYFOLCFWQWQG-UHFFFAOYSA-N octane;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCCCCCCC DJLYFOLCFWQWQG-UHFFFAOYSA-N 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 5
- 229940100198 alkylating agent Drugs 0.000 description 5
- 239000002168 alkylating agent Substances 0.000 description 5
- 238000004440 column chromatography Methods 0.000 description 5
- IVLICPVPXWEGCA-ZETCQYMHSA-N (3r)-1-azabicyclo[2.2.2]octan-3-ol Chemical compound C1CC2[C@@H](O)CN1CC2 IVLICPVPXWEGCA-ZETCQYMHSA-N 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 4
- 239000012267 brine Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 125000005842 heteroatom Chemical group 0.000 description 4
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- KJAMZCVTJDTESW-UHFFFAOYSA-N tiracizine Chemical compound C1CC2=CC=CC=C2N(C(=O)CN(C)C)C2=CC(NC(=O)OCC)=CC=C21 KJAMZCVTJDTESW-UHFFFAOYSA-N 0.000 description 4
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 4
- 230000002485 urinary effect Effects 0.000 description 4
- CXDCHKYMBPRDKI-UHFFFAOYSA-N (4-fluoro-2-methylphenyl)-[(3-methylthiophen-2-yl)methyl]carbamic acid Chemical compound C1=CSC(CN(C(O)=O)C=2C(=CC(F)=CC=2)C)=C1C CXDCHKYMBPRDKI-UHFFFAOYSA-N 0.000 description 3
- DSTLXMSUVMLNBP-UHFFFAOYSA-N 1-azoniabicyclo[2.2.2]octane;carbamate Chemical class NC(O)=O.C1CC2CCN1CC2 DSTLXMSUVMLNBP-UHFFFAOYSA-N 0.000 description 3
- QZVQQUVWFIZUBQ-UHFFFAOYSA-N 3-fluoroaniline Chemical compound NC1=CC=CC(F)=C1 QZVQQUVWFIZUBQ-UHFFFAOYSA-N 0.000 description 3
- 208000009079 Bronchial Spasm Diseases 0.000 description 3
- 208000014181 Bronchial disease Diseases 0.000 description 3
- 206010006482 Bronchospasm Diseases 0.000 description 3
- CKDWPUIZGOQOOM-UHFFFAOYSA-N Carbamyl chloride Chemical compound NC(Cl)=O CKDWPUIZGOQOOM-UHFFFAOYSA-N 0.000 description 3
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 125000002723 alicyclic group Chemical group 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- SNBFKFGZVPBMII-UHFFFAOYSA-N bis(thiophen-2-ylmethyl)carbamic acid Chemical compound C=1C=CSC=1CN(C(=O)O)CC1=CC=CS1 SNBFKFGZVPBMII-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002808 molecular sieve Substances 0.000 description 3
- AGQBMOPMVQITGC-UHFFFAOYSA-N n-[2-(4-fluorophenyl)ethyl]-n-[(3-methylthiophen-2-yl)methyl]carbamoyl chloride Chemical compound C1=CSC(CN(CCC=2C=CC(F)=CC=2)C(Cl)=O)=C1C AGQBMOPMVQITGC-UHFFFAOYSA-N 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- HZOXALVFNQWNFV-UHFFFAOYSA-N phenyl(thiophen-3-ylmethyl)carbamic acid Chemical compound C=1C=CC=CC=1N(C(=O)O)CC=1C=CSC=1 HZOXALVFNQWNFV-UHFFFAOYSA-N 0.000 description 3
- 125000003226 pyrazolyl group Chemical group 0.000 description 3
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 3
- 238000005932 reductive alkylation reaction Methods 0.000 description 3
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- LYWPHZOURPALOY-UHFFFAOYSA-N (3-methylphenyl)-[(2,4,5-trifluorophenyl)methyl]carbamic acid Chemical compound CC1=CC=CC(N(CC=2C(=CC(F)=C(F)C=2)F)C(O)=O)=C1 LYWPHZOURPALOY-UHFFFAOYSA-N 0.000 description 2
- ZLSXJACUYPTAFK-UHFFFAOYSA-N (5-bromothiophen-2-yl)methyl-(2,4,5-trifluorophenyl)carbamic acid Chemical compound C=1C(F)=C(F)C=C(F)C=1N(C(=O)O)CC1=CC=C(Br)S1 ZLSXJACUYPTAFK-UHFFFAOYSA-N 0.000 description 2
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 2
- DSNGLKATJGBVIX-UHFFFAOYSA-N 1-azabicyclo[2.2.1]heptan-4-ol Chemical compound C1CN2CCC1(O)C2 DSNGLKATJGBVIX-UHFFFAOYSA-N 0.000 description 2
- DYEHDACATJUKSZ-UHFFFAOYSA-N 1-azoniabicyclo[2.2.2]octane;bromide Chemical compound [Br-].C1CC2CC[NH+]1CC2 DYEHDACATJUKSZ-UHFFFAOYSA-N 0.000 description 2
- ANOUKFYBOAKOIR-UHFFFAOYSA-N 3,4-dimethoxyphenylethylamine Chemical compound COC1=CC=C(CCN)C=C1OC ANOUKFYBOAKOIR-UHFFFAOYSA-N 0.000 description 2
- HCPTUKROWNAPOK-UHFFFAOYSA-N 3-methyl-n-[(2,4,5-trifluorophenyl)methyl]aniline Chemical compound CC1=CC=CC(NCC=2C(=CC(F)=C(F)C=2)F)=C1 HCPTUKROWNAPOK-UHFFFAOYSA-N 0.000 description 2
- OUDFNZMQXZILJD-UHFFFAOYSA-N 5-methyl-2-furaldehyde Chemical compound CC1=CC=C(C=O)O1 OUDFNZMQXZILJD-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000017925 CHRM3 Human genes 0.000 description 2
- 101150060249 CHRM3 gene Proteins 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 206010063057 Cystitis noninfective Diseases 0.000 description 2
- 206010020853 Hypertonic bladder Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102000007202 Muscarinic M3 Receptor Human genes 0.000 description 2
- 108010008405 Muscarinic M3 Receptor Proteins 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- 208000000693 Neurogenic Urinary Bladder Diseases 0.000 description 2
- 206010029279 Neurogenic bladder Diseases 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 206010046543 Urinary incontinence Diseases 0.000 description 2
- RUMIBZGNGQBYPD-DSSKCDFUSA-M [(3r)-1-(2-phenoxyethyl)-1-azoniabicyclo[2.2.2]octan-3-yl] n-phenyl-n-(thiophen-3-ylmethyl)carbamate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)N(CC3=CSC=C3)C=3C=CC=CC=3)[N+]21CCOC1=CC=CC=C1 RUMIBZGNGQBYPD-DSSKCDFUSA-M 0.000 description 2
- QFIZIGQWSJFUKW-QHCPKHFHSA-N [(3r)-1-azabicyclo[2.2.2]octan-3-yl] n-[2-(3,4-dimethoxyphenyl)ethyl]-n-[(5-methylfuran-2-yl)methyl]carbamate Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C(=O)O[C@@H]1C2CCN(CC2)C1)CC1=CC=C(C)O1 QFIZIGQWSJFUKW-QHCPKHFHSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 239000000908 ammonium hydroxide Substances 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- BAIBBRORQJDVKQ-UHFFFAOYSA-N benzyl-(4-methylphenyl)carbamic acid Chemical compound C1=CC(C)=CC=C1N(C(O)=O)CC1=CC=CC=C1 BAIBBRORQJDVKQ-UHFFFAOYSA-N 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- XWDAJKMDKMCFKY-UHFFFAOYSA-N bis(furan-2-ylmethyl)carbamic acid Chemical compound O1C(=CC=C1)CN(C(O)=O)CC=1OC=CC1 XWDAJKMDKMCFKY-UHFFFAOYSA-N 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- CEWKHVQYIATTIC-UHFFFAOYSA-N butyl(phenyl)carbamic acid Chemical compound CCCCN(C(O)=O)C1=CC=CC=C1 CEWKHVQYIATTIC-UHFFFAOYSA-N 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 201000003139 chronic cystitis Diseases 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 206010009887 colitis Diseases 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- DXKTZGOWHPTUBX-UHFFFAOYSA-N cyclohexylmethyl-(2-fluorophenyl)carbamic acid Chemical compound C=1C=CC=C(F)C=1N(C(=O)O)CC1CCCCC1 DXKTZGOWHPTUBX-UHFFFAOYSA-N 0.000 description 2
- YQYXDECZRWZKKY-UHFFFAOYSA-N cyclopentyl(thiophen-2-ylmethyl)carbamic acid Chemical compound C1CCCC1N(C(=O)O)CC1=CC=CS1 YQYXDECZRWZKKY-UHFFFAOYSA-N 0.000 description 2
- AOBXNWWEUYWATH-UHFFFAOYSA-N cyclopentyl-[(4,5-dimethylthiophen-2-yl)methyl]carbamic acid Chemical compound S1C(C)=C(C)C=C1CN(C(O)=O)C1CCCC1 AOBXNWWEUYWATH-UHFFFAOYSA-N 0.000 description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 208000007784 diverticulitis Diseases 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 150000004675 formic acid derivatives Chemical class 0.000 description 2
- GTDGMPIWFRMGNK-UHFFFAOYSA-N furan-2-ylmethyl(phenyl)carbamic acid Chemical compound C=1C=CC=CC=1N(C(=O)O)CC1=CC=CO1 GTDGMPIWFRMGNK-UHFFFAOYSA-N 0.000 description 2
- 230000000762 glandular Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- 125000005956 isoquinolyl group Chemical group 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 239000003149 muscarinic antagonist Substances 0.000 description 2
- UTGDDKPFAFNFJS-UHFFFAOYSA-N n-cyclopentyl-n-(thiophen-2-ylmethyl)carbamoyl chloride Chemical compound C1CCCC1N(C(=O)Cl)CC1=CC=CS1 UTGDDKPFAFNFJS-UHFFFAOYSA-N 0.000 description 2
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 2
- SRHHXHOIKKDDOY-UHFFFAOYSA-N octane;hydroiodide Chemical compound I.CCCCCCCC SRHHXHOIKKDDOY-UHFFFAOYSA-N 0.000 description 2
- 229940039748 oxalate Drugs 0.000 description 2
- 230000001734 parasympathetic effect Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- OLTPKMBOLARPFC-UHFFFAOYSA-N phenyl(2-phenylethyl)carbamic acid Chemical compound C=1C=CC=CC=1N(C(=O)O)CCC1=CC=CC=C1 OLTPKMBOLARPFC-UHFFFAOYSA-N 0.000 description 2
- MZEJYTHCXCYSHD-UHFFFAOYSA-N phenyl(thiophen-2-ylmethyl)carbamic acid Chemical compound C=1C=CC=CC=1N(C(=O)O)CC1=CC=CS1 MZEJYTHCXCYSHD-UHFFFAOYSA-N 0.000 description 2
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 125000005493 quinolyl group Chemical group 0.000 description 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 206010039083 rhinitis Diseases 0.000 description 2
- 150000003335 secondary amines Chemical class 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000001148 spastic effect Effects 0.000 description 2
- 229940086735 succinate Drugs 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- 125000001425 triazolyl group Chemical group 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- MJFMNPHJODJIBF-UHFFFAOYSA-N (2,4,5-trifluorophenyl)methylcarbamic acid Chemical compound OC(=O)NCC1=CC(F)=C(F)C=C1F MJFMNPHJODJIBF-UHFFFAOYSA-N 0.000 description 1
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
- MXKGMIUPTIDTBM-UHFFFAOYSA-N (3-fluorophenyl)-[(3-fluorophenyl)methyl]carbamic acid Chemical compound C=1C=CC(F)=CC=1N(C(=O)O)CC1=CC=CC(F)=C1 MXKGMIUPTIDTBM-UHFFFAOYSA-N 0.000 description 1
- MAYZWDRUFKUGGP-VIFPVBQESA-N (3s)-1-[5-tert-butyl-3-[(1-methyltetrazol-5-yl)methyl]triazolo[4,5-d]pyrimidin-7-yl]pyrrolidin-3-ol Chemical compound CN1N=NN=C1CN1C2=NC(C(C)(C)C)=NC(N3C[C@@H](O)CC3)=C2N=N1 MAYZWDRUFKUGGP-VIFPVBQESA-N 0.000 description 1
- IVLICPVPXWEGCA-SSDOTTSWSA-N (3s)-1-azabicyclo[2.2.2]octan-3-ol Chemical compound C1CC2[C@H](O)CN1CC2 IVLICPVPXWEGCA-SSDOTTSWSA-N 0.000 description 1
- KEQMVQOKLVLGKG-UHFFFAOYSA-N (4-bromo-5-methylthiophen-2-yl)methyl-[(3-methylthiophen-2-yl)methyl]carbamic acid Chemical compound C1=CSC(CN(CC=2SC(C)=C(Br)C=2)C(O)=O)=C1C KEQMVQOKLVLGKG-UHFFFAOYSA-N 0.000 description 1
- ZGYIXVSQHOKQRZ-COIATFDQSA-N (e)-n-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-[(3s)-oxolan-3-yl]oxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide Chemical compound N#CC1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZGYIXVSQHOKQRZ-COIATFDQSA-N 0.000 description 1
- MOWXJLUYGFNTAL-DEOSSOPVSA-N (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol Chemical compound N1=NC(OC)=CC=C1[C@@H](O)C1=CC(C=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C(F)C=C1Cl MOWXJLUYGFNTAL-DEOSSOPVSA-N 0.000 description 1
- APWRZPQBPCAXFP-UHFFFAOYSA-N 1-(1-oxo-2H-isoquinolin-5-yl)-5-(trifluoromethyl)-N-[2-(trifluoromethyl)pyridin-4-yl]pyrazole-4-carboxamide Chemical compound O=C1NC=CC2=C(C=CC=C12)N1N=CC(=C1C(F)(F)F)C(=O)NC1=CC(=NC=C1)C(F)(F)F APWRZPQBPCAXFP-UHFFFAOYSA-N 0.000 description 1
- ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 1
- IJIHPPHWXPHTRG-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-yl n,n-diphenylcarbamate Chemical compound C1N(CC2)CCC2C1OC(=O)N(C=1C=CC=CC=1)C1=CC=CC=C1 IJIHPPHWXPHTRG-UHFFFAOYSA-N 0.000 description 1
- RQRSQXFVRUWISR-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-4-ol Chemical compound C1CN2CCC1(O)CC2 RQRSQXFVRUWISR-UHFFFAOYSA-N 0.000 description 1
- OUJMNRNXTLOPJI-UHFFFAOYSA-N 1-azoniabicyclo[2.2.2]octan-1-yl N-benzyl-N-phenylcarbamate Chemical compound C(C1=CC=CC=C1)N(C(=O)O[N+]12CCC(CC1)CC2)C1=CC=CC=C1 OUJMNRNXTLOPJI-UHFFFAOYSA-N 0.000 description 1
- USPDKXJEZWRPBT-UHFFFAOYSA-N 1-azoniabicyclo[2.2.2]octan-1-yl N-phenyl-N-(thiophen-2-ylmethyl)carbamate Chemical compound C1(=CC=CC=C1)N(C(=O)O[N+]12CCC(CC1)CC2)CC=1SC=CC=1 USPDKXJEZWRPBT-UHFFFAOYSA-N 0.000 description 1
- LSXKDWGTSHCFPP-UHFFFAOYSA-N 1-bromoheptane Chemical compound CCCCCCCBr LSXKDWGTSHCFPP-UHFFFAOYSA-N 0.000 description 1
- 125000006218 1-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- MFQQHFRKVCFEBQ-UHFFFAOYSA-N 1-methyl-1-azoniabicyclo[2.2.2]octane Chemical compound C1CC2CC[N+]1(C)CC2 MFQQHFRKVCFEBQ-UHFFFAOYSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- YYABOYVMXVMNPF-UHFFFAOYSA-N 2,2,2-trifluoroacetic acid;hydrobromide Chemical compound Br.OC(=O)C(F)(F)F YYABOYVMXVMNPF-UHFFFAOYSA-N 0.000 description 1
- QMYVWJVVVMIBMM-UHFFFAOYSA-N 2,4,5-trifluoroaniline Chemical compound NC1=CC(F)=C(F)C=C1F QMYVWJVVVMIBMM-UHFFFAOYSA-N 0.000 description 1
- WUBZVWLDMUDMRL-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-n-[(5-methylfuran-2-yl)methyl]ethanamine Chemical compound C1=C(OC)C(OC)=CC=C1CCNCC1=CC=C(C)O1 WUBZVWLDMUDMRL-UHFFFAOYSA-N 0.000 description 1
- JARYHXHZIFTPKI-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)ethyl-[(5-methylfuran-2-yl)methyl]carbamic acid Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C(O)=O)CC1=CC=C(C)O1 JARYHXHZIFTPKI-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 description 1
- JJFOBACUIRKUPN-UHFFFAOYSA-N 2-bromoethoxybenzene Chemical compound BrCCOC1=CC=CC=C1 JJFOBACUIRKUPN-UHFFFAOYSA-N 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- BYHQTRFJOGIQAO-GOSISDBHSA-N 3-(4-bromophenyl)-8-[(2R)-2-hydroxypropyl]-1-[(3-methoxyphenyl)methyl]-1,3,8-triazaspiro[4.5]decan-2-one Chemical compound C[C@H](CN1CCC2(CC1)CN(C(=O)N2CC3=CC(=CC=C3)OC)C4=CC=C(C=C4)Br)O BYHQTRFJOGIQAO-GOSISDBHSA-N 0.000 description 1
- SRVXSISGYBMIHR-UHFFFAOYSA-N 3-[3-[3-(2-amino-2-oxoethyl)phenyl]-5-chlorophenyl]-3-(5-methyl-1,3-thiazol-2-yl)propanoic acid Chemical compound S1C(C)=CN=C1C(CC(O)=O)C1=CC(Cl)=CC(C=2C=C(CC(N)=O)C=CC=2)=C1 SRVXSISGYBMIHR-UHFFFAOYSA-N 0.000 description 1
- IKVJFSFQVZYWRX-UHFFFAOYSA-N 3-fluoro-4-methoxy-n-(thiophen-3-ylmethyl)aniline Chemical compound C1=C(F)C(OC)=CC=C1NCC1=CSC=C1 IKVJFSFQVZYWRX-UHFFFAOYSA-N 0.000 description 1
- SMJWCIJUYKXZHU-UHFFFAOYSA-N 3-fluoro-n-[(3,4,5-trifluorophenyl)methyl]aniline Chemical compound FC1=CC=CC(NCC=2C=C(F)C(F)=C(F)C=2)=C1 SMJWCIJUYKXZHU-UHFFFAOYSA-N 0.000 description 1
- JJYPMNFTHPTTDI-UHFFFAOYSA-N 3-methylaniline Chemical compound CC1=CC=CC(N)=C1 JJYPMNFTHPTTDI-UHFFFAOYSA-N 0.000 description 1
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- YFCIFWOJYYFDQP-PTWZRHHISA-N 4-[3-amino-6-[(1S,3S,4S)-3-fluoro-4-hydroxycyclohexyl]pyrazin-2-yl]-N-[(1S)-1-(3-bromo-5-fluorophenyl)-2-(methylamino)ethyl]-2-fluorobenzamide Chemical compound CNC[C@@H](NC(=O)c1ccc(cc1F)-c1nc(cnc1N)[C@H]1CC[C@H](O)[C@@H](F)C1)c1cc(F)cc(Br)c1 YFCIFWOJYYFDQP-PTWZRHHISA-N 0.000 description 1
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
- MPEKZIYOLQCWLL-UHFFFAOYSA-N 5-(bromomethyl)-1,2,3-trifluorobenzene Chemical compound FC1=CC(CBr)=CC(F)=C1F MPEKZIYOLQCWLL-UHFFFAOYSA-N 0.000 description 1
- GFBVUFQNHLUCPX-UHFFFAOYSA-N 5-bromothiophene-2-carbaldehyde Chemical compound BrC1=CC=C(C=O)S1 GFBVUFQNHLUCPX-UHFFFAOYSA-N 0.000 description 1
- KCBWAFJCKVKYHO-UHFFFAOYSA-N 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-[[4-[1-propan-2-yl-4-(trifluoromethyl)imidazol-2-yl]phenyl]methyl]pyrazolo[3,4-d]pyrimidine Chemical compound C1(CC1)C1=NC=NC(=C1C1=NC=C2C(=N1)N(N=C2)CC1=CC=C(C=C1)C=1N(C=C(N=1)C(F)(F)F)C(C)C)OC KCBWAFJCKVKYHO-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 206010066091 Bronchial Hyperreactivity Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- PNWQOMABRMWDMF-IHNSNXCOSA-M C(C1=CC=CC=C1)N(C(=O)O[C@@H]1C[N+]2(CCC1CC2)CCCC1=CC=CC=C1)C1=CC=CC=C1.[Br-] Chemical compound C(C1=CC=CC=C1)N(C(=O)O[C@@H]1C[N+]2(CCC1CC2)CCCC1=CC=CC=C1)C1=CC=CC=C1.[Br-] PNWQOMABRMWDMF-IHNSNXCOSA-M 0.000 description 1
- PYOXBZOHIXTCIJ-UHFFFAOYSA-N C1CCC(C1)N(CC2=CC=CS2)C(=O)OC3CC4CC[N+]3(CC4)CCCC5=CC=CC=C5 Chemical compound C1CCC(C1)N(CC2=CC=CS2)C(=O)OC3CC4CC[N+]3(CC4)CCCC5=CC=CC=C5 PYOXBZOHIXTCIJ-UHFFFAOYSA-N 0.000 description 1
- BLKAMJLTNLIDRC-QHXXGYRJSA-N CC(C1=CC=CC=C1)[N+]1(CCC2CC1)C[C@@H]2OC(N(CC1=CSC=C1)CC(C=C(C(F)=C1)F)=C1F)=O Chemical compound CC(C1=CC=CC=C1)[N+]1(CCC2CC1)C[C@@H]2OC(N(CC1=CSC=C1)CC(C=C(C(F)=C1)F)=C1F)=O BLKAMJLTNLIDRC-QHXXGYRJSA-N 0.000 description 1
- 102000017926 CHRM2 Human genes 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- 101150012960 Chrm2 gene Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- BRDWIEOJOWJCLU-LTGWCKQJSA-N GS-441524 Chemical compound C=1C=C2C(N)=NC=NN2C=1[C@]1(C#N)O[C@H](CO)[C@@H](O)[C@H]1O BRDWIEOJOWJCLU-LTGWCKQJSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical class O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- IDRGFNPZDVBSSE-UHFFFAOYSA-N OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F Chemical compound OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F IDRGFNPZDVBSSE-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 206010036018 Pollakiuria Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010040741 Sinus bradycardia Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- LXRZVMYMQHNYJB-UNXOBOICSA-N [(1R,2S,4R)-4-[[5-[4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate Chemical compound CC1=C(C=C(S1)C(=O)C1=C(N[C@H]2C[C@H](O)[C@@H](COS(N)(=O)=O)C2)N=CN=C1)[C@@H]1NCCC2=C1C=C(Cl)C=C2 LXRZVMYMQHNYJB-UNXOBOICSA-N 0.000 description 1
- SHOVMVLVQTWJHE-IMYXXEESSA-N [(2R)-1-(2-hydroxyethyl)-1-azoniabicyclo[2.2.2]octan-2-yl] N-butyl-N-phenylcarbamate Chemical compound C(CCC)N(C(=O)O[C@H]1[N+]2(CCC(C1)CC2)CCO)C1=CC=CC=C1 SHOVMVLVQTWJHE-IMYXXEESSA-N 0.000 description 1
- KJSQDELEDLJGHZ-UUTHKHQDSA-N [(3R)-1-(1-phenylethyl)-1-azoniabicyclo[2.2.2]octan-3-yl] N-butyl-N-phenylcarbamate Chemical compound C([C@@H](C(CC1)CC2)OC(=O)N(CCCC)C=3C=CC=CC=3)[N+]21C(C)C1=CC=CC=C1 KJSQDELEDLJGHZ-UUTHKHQDSA-N 0.000 description 1
- KIVRXTXQVSUHHY-SUPQUVAKSA-M [(3R)-1-[2-(2-methoxyethoxy)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] N-benzyl-N-phenylcarbamate bromide Chemical compound C(C1=CC=CC=C1)N(C(=O)O[C@H]1C[N+]2(CCC1CC2)CCOCCOC)C1=CC=CC=C1.[Br-] KIVRXTXQVSUHHY-SUPQUVAKSA-M 0.000 description 1
- OPEODEHKLCUUJI-MNFPOUGWSA-M [(3R)-1-[3-(4-fluorophenoxy)propyl]-1-azoniabicyclo[2.2.2]octan-3-yl] N-butyl-N-phenylcarbamate chloride Chemical compound C(CCC)N(C(=O)O[C@H]1C[N+]2(CCC1CC2)CCCOC1=CC=C(C=C1)F)C1=CC=CC=C1.[Cl-] OPEODEHKLCUUJI-MNFPOUGWSA-M 0.000 description 1
- FTARAIZZZVPUJB-XBXIBHRUSA-N [(3r)-1-(1-phenylethyl)-1-azoniabicyclo[2.2.2]octan-3-yl] n-benzyl-n-phenylcarbamate Chemical compound C1CC([C@H](C2)OC(=O)N(CC=3C=CC=CC=3)C=3C=CC=CC=3)CC[N+]12C(C)C1=CC=CC=C1 FTARAIZZZVPUJB-XBXIBHRUSA-N 0.000 description 1
- NOZVXMJLWNBZBB-YIPDAYQMSA-N [(3r)-1-(2-phenoxyethyl)-1-azoniabicyclo[2.2.2]octan-3-yl] n-(3-fluorophenyl)-n-[(3-fluorophenyl)methyl]carbamate Chemical compound FC1=CC=CC(CN(C(=O)O[C@@H]2C3CC[N+](CC3)(CCOC=3C=CC=CC=3)C2)C=2C=C(F)C=CC=2)=C1 NOZVXMJLWNBZBB-YIPDAYQMSA-N 0.000 description 1
- SFGQXEQZTVTLDH-XAEROCQYSA-M [(3r)-1-(2-phenoxyethyl)-1-azoniabicyclo[2.2.2]octan-3-yl] n-(4-fluoro-2-methylphenyl)-n-[(3-methylthiophen-2-yl)methyl]carbamate;bromide Chemical compound [Br-].C1=CSC(CN(C(=O)O[C@@H]2C3CC[N+](CC3)(CCOC=3C=CC=CC=3)C2)C=2C(=CC(F)=CC=2)C)=C1C SFGQXEQZTVTLDH-XAEROCQYSA-M 0.000 description 1
- GDLWJBJOVTYAJR-GSEXTUOBSA-M [(3r)-1-(2-phenoxyethyl)-1-azoniabicyclo[2.2.2]octan-3-yl] n-benzyl-n-phenylcarbamate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)N(CC=3C=CC=CC=3)C=3C=CC=CC=3)[N+]21CCOC1=CC=CC=C1 GDLWJBJOVTYAJR-GSEXTUOBSA-M 0.000 description 1
- CXRIFSPGYWTKPW-OKBRVIPFSA-N [(3r)-1-(2-phenoxyethyl)-1-azoniabicyclo[2.2.2]octan-3-yl] n-butyl-n-phenylcarbamate Chemical compound C([C@@H](C(CC1)CC2)OC(=O)N(CCCC)C=3C=CC=CC=3)[N+]21CCOC1=CC=CC=C1 CXRIFSPGYWTKPW-OKBRVIPFSA-N 0.000 description 1
- PAZJAFKVOUZUPG-RARKWRLQSA-M [(3r)-1-(2-phenoxyethyl)-1-azoniabicyclo[2.2.2]octan-3-yl] n-phenyl-n-(2-phenylethyl)carbamate;2,2,2-trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F.C([C@@H](C(CC1)CC2)OC(=O)N(CCC=3C=CC=CC=3)C=3C=CC=CC=3)[N+]21CCOC1=CC=CC=C1 PAZJAFKVOUZUPG-RARKWRLQSA-M 0.000 description 1
- HSGQPXOPCPJENX-CCOWBORGSA-M [(3r)-1-(2-phenoxyethyl)-1-azoniabicyclo[2.2.2]octan-3-yl] n-phenyl-n-(thiophen-2-ylmethyl)carbamate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)N(CC=3SC=CC=3)C=3C=CC=CC=3)[N+]21CCOC1=CC=CC=C1 HSGQPXOPCPJENX-CCOWBORGSA-M 0.000 description 1
- SYRVXBDLMMPFEM-ROTRRZJSSA-N [(3r)-1-(2-phenylmethoxyethyl)-1-azoniabicyclo[2.2.2]octan-3-yl] n-phenyl-n-(thiophen-2-ylmethyl)carbamate Chemical compound C([C@@H](C(CC1)CC2)OC(=O)N(CC=3SC=CC=3)C=3C=CC=CC=3)[N+]21CCOCC1=CC=CC=C1 SYRVXBDLMMPFEM-ROTRRZJSSA-N 0.000 description 1
- CRNULVRCQATHCB-IIIFQBMYSA-N [(3r)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octan-3-yl] n-benzyl-n-phenylcarbamate Chemical compound C([C@@H](C(CC1)CC2)OC(=O)N(CC=3C=CC=CC=3)C=3C=CC=CC=3)[N+]21CCCOC1=CC=CC=C1 CRNULVRCQATHCB-IIIFQBMYSA-N 0.000 description 1
- RFHYCEHWBDUMOY-AEDYTTQKSA-M [(3r)-1-(3-phenylpropyl)-1-azoniabicyclo[2.2.2]octan-3-yl] n-(furan-2-ylmethyl)-n-phenylcarbamate;2,2,2-trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F.C([C@@H](C(CC1)CC2)OC(=O)N(CC=3OC=CC=3)C=3C=CC=CC=3)[N+]21CCCC1=CC=CC=C1 RFHYCEHWBDUMOY-AEDYTTQKSA-M 0.000 description 1
- ZUICJRIEMALFLN-HAMJSAHASA-N [(3r)-1-(3-phenylpropyl)-1-azoniabicyclo[2.2.2]octan-3-yl] n-benzyl-n-phenylcarbamate Chemical compound C([C@@H](C(CC1)CC2)OC(=O)N(CC=3C=CC=CC=3)C=3C=CC=CC=3)[N+]21CCCC1=CC=CC=C1 ZUICJRIEMALFLN-HAMJSAHASA-N 0.000 description 1
- PNWQOMABRMWDMF-LVKSKBLHSA-M [(3r)-1-(3-phenylpropyl)-1-azoniabicyclo[2.2.2]octan-3-yl] n-benzyl-n-phenylcarbamate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)N(CC=3C=CC=CC=3)C=3C=CC=CC=3)[N+]21CCCC1=CC=CC=C1 PNWQOMABRMWDMF-LVKSKBLHSA-M 0.000 description 1
- ZEKWXBFSCSXDLQ-NRMJQQDLSA-M [(3r)-1-(3-phenylpropyl)-1-azoniabicyclo[2.2.2]octan-3-yl] n-butyl-n-phenylcarbamate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)N(CCCC)C=3C=CC=CC=3)[N+]21CCCC1=CC=CC=C1 ZEKWXBFSCSXDLQ-NRMJQQDLSA-M 0.000 description 1
- MCGSMQKZGMDZFT-AEDYTTQKSA-M [(3r)-1-(3-thiophen-2-ylpropyl)-1-azoniabicyclo[2.2.2]octan-3-yl] n-benzyl-n-phenylcarbamate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)N(CC=3C=CC=CC=3)C=3C=CC=CC=3)[N+]21CCCC1=CC=CS1 MCGSMQKZGMDZFT-AEDYTTQKSA-M 0.000 description 1
- FHESLQGDLROIOJ-SSVLGJNASA-M [(3r)-1-(3-thiophen-2-ylpropyl)-1-azoniabicyclo[2.2.2]octan-3-yl] n-butyl-n-phenylcarbamate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)N(CCCC)C=3C=CC=CC=3)[N+]21CCCC1=CC=CS1 FHESLQGDLROIOJ-SSVLGJNASA-M 0.000 description 1
- ZGAIDOGAKIQCJU-FJOOJYTASA-N [(3r)-1-(3-thiophen-2-ylpropyl)-1-azoniabicyclo[2.2.2]octan-3-yl] n-phenyl-n-(thiophen-2-ylmethyl)carbamate Chemical compound C([C@@H](C(CC1)CC2)OC(=O)N(CC=3SC=CC=3)C=3C=CC=CC=3)[N+]21CCCC1=CC=CS1 ZGAIDOGAKIQCJU-FJOOJYTASA-N 0.000 description 1
- DIQXIWJNNCBKDZ-OKBRVIPFSA-N [(3r)-1-(3-thiophen-2-ylpropyl)-1-azoniabicyclo[2.2.2]octan-3-yl] n-phenyl-n-(thiophen-3-ylmethyl)carbamate Chemical compound C([C@@H](C(CC1)CC2)OC(=O)N(CC3=CSC=C3)C=3C=CC=CC=3)[N+]21CCCC1=CC=CS1 DIQXIWJNNCBKDZ-OKBRVIPFSA-N 0.000 description 1
- SAQHUZWTXIFWGY-CVCZCXRASA-N [(3r)-1-[2-(2-methoxyethoxy)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] n-butyl-n-phenylcarbamate Chemical compound O([C@@H]1C2CC[N+](CC2)(CCOCCOC)C1)C(=O)N(CCCC)C1=CC=CC=C1 SAQHUZWTXIFWGY-CVCZCXRASA-N 0.000 description 1
- CXTDREZIFCNIQA-AUSLDBMVSA-O [(3r)-1-[3-(3-hydroxyphenoxy)propyl]-1-azoniabicyclo[2.2.2]octan-3-yl] n-phenyl-n-(thiophen-2-ylmethyl)carbamate Chemical compound OC1=CC=CC(OCCC[N+]23CCC(CC2)[C@H](C3)OC(=O)N(CC=2SC=CC=2)C=2C=CC=CC=2)=C1 CXTDREZIFCNIQA-AUSLDBMVSA-O 0.000 description 1
- URDXFKMXLZZTRI-FQEVSTJZSA-N [(3r)-1-azabicyclo[2.2.2]octan-3-yl] n-(3-fluorophenyl)-n-[(3-fluorophenyl)methyl]carbamate Chemical compound FC1=CC=CC(CN(C(=O)O[C@@H]2C3CCN(CC3)C2)C=2C=C(F)C=CC=2)=C1 URDXFKMXLZZTRI-FQEVSTJZSA-N 0.000 description 1
- CLOSPRMVOVWGOW-SFHVURJKSA-N [(3r)-1-azabicyclo[2.2.2]octan-3-yl] n-[(4-bromo-5-methylthiophen-2-yl)methyl]-n-[(3-methylthiophen-2-yl)methyl]carbamate Chemical compound C1=CSC(CN(CC=2SC(C)=C(Br)C=2)C(=O)O[C@@H]2C3CCN(CC3)C2)=C1C CLOSPRMVOVWGOW-SFHVURJKSA-N 0.000 description 1
- QPRWDHVZZSSIHZ-QMAMVGRZSA-M [Br-].C1CC([C@H](C2)OC(=O)N(CC=3C=CC=CC=3)C=3C=CC=CC=3)CC[N+]12C(C)C1=CC=CC=C1 Chemical compound [Br-].C1CC([C@H](C2)OC(=O)N(CC=3C=CC=CC=3)C=3C=CC=CC=3)CC[N+]12C(C)C1=CC=CC=C1 QPRWDHVZZSSIHZ-QMAMVGRZSA-M 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000000078 anti-malarial effect Effects 0.000 description 1
- 230000001022 anti-muscarinic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- CQAMPEQWAJLGTK-UHFFFAOYSA-N benzyl-(4-fluorophenyl)carbamic acid Chemical compound C=1C=C(F)C=CC=1N(C(=O)O)CC1=CC=CC=C1 CQAMPEQWAJLGTK-UHFFFAOYSA-N 0.000 description 1
- 229940125388 beta agonist Drugs 0.000 description 1
- 230000036427 bronchial hyperreactivity Effects 0.000 description 1
- 230000010083 bronchial hyperresponsiveness Effects 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- AIRBJINEBYGVJZ-UHFFFAOYSA-N butyl(thiophen-2-ylmethyl)carbamic acid Chemical compound CCCCN(C(O)=O)CC1=CC=CS1 AIRBJINEBYGVJZ-UHFFFAOYSA-N 0.000 description 1
- JLABSCKALQQSHY-UHFFFAOYSA-N butyl-(2,5-difluorophenyl)carbamic acid Chemical compound CCCCN(C(O)=O)C1=CC(F)=CC=C1F JLABSCKALQQSHY-UHFFFAOYSA-N 0.000 description 1
- VCJUJZHGRYCPGJ-UHFFFAOYSA-N butyl-(4-fluorophenyl)carbamic acid Chemical compound CCCCN(C(O)=O)C1=CC=C(F)C=C1 VCJUJZHGRYCPGJ-UHFFFAOYSA-N 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 150000001793 charged compounds Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000013066 combination product Substances 0.000 description 1
- 229940127555 combination product Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- GABQKHQNXWNJJJ-UHFFFAOYSA-N diphenylcarbamic acid Chemical compound C=1C=CC=CC=1N(C(=O)O)C1=CC=CC=C1 GABQKHQNXWNJJJ-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- AFRWBGJRWRHQOV-UHFFFAOYSA-N ethyl 5-bromopentanoate Chemical compound CCOC(=O)CCCCBr AFRWBGJRWRHQOV-UHFFFAOYSA-N 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229940031705 hydroxypropyl methylcellulose 2910 Drugs 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940098453 inhalant powder Drugs 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- GXGVFLSIWJNVBZ-UHFFFAOYSA-N n-(3-fluoro-4-methoxyphenyl)-n-(thiophen-3-ylmethyl)carbamoyl chloride Chemical compound C1=C(F)C(OC)=CC=C1N(C(Cl)=O)CC1=CSC=C1 GXGVFLSIWJNVBZ-UHFFFAOYSA-N 0.000 description 1
- LZYBSVKXAZOCKO-UHFFFAOYSA-N n-(3-fluorophenyl)-n-[(3,4,5-trifluorophenyl)methyl]carbamoyl chloride Chemical compound FC1=CC=CC(N(CC=2C=C(F)C(F)=C(F)C=2)C(Cl)=O)=C1 LZYBSVKXAZOCKO-UHFFFAOYSA-N 0.000 description 1
- XXBUKAHFSCLGJI-UHFFFAOYSA-N n-(3-fluorophenyl)-n-[(3-fluorophenyl)methyl]carbamoyl chloride Chemical compound FC1=CC=CC(CN(C(Cl)=O)C=2C=C(F)C=CC=2)=C1 XXBUKAHFSCLGJI-UHFFFAOYSA-N 0.000 description 1
- WGIFDITYLWFHFL-UHFFFAOYSA-N n-(4-fluoro-2-methylphenyl)-n-[(3-methylthiophen-2-yl)methyl]carbamoyl chloride Chemical compound C1=CSC(CN(C(Cl)=O)C=2C(=CC(F)=CC=2)C)=C1C WGIFDITYLWFHFL-UHFFFAOYSA-N 0.000 description 1
- RYTAWEJFPWUHAM-UHFFFAOYSA-N n-(4-phenylbutyl)carbamoyl chloride Chemical compound ClC(=O)NCCCCC1=CC=CC=C1 RYTAWEJFPWUHAM-UHFFFAOYSA-N 0.000 description 1
- CRLHPNUFQXBBAO-UHFFFAOYSA-N n-(thiophen-2-ylmethyl)cyclopentanamine Chemical compound C=1C=CSC=1CNC1CCCC1 CRLHPNUFQXBBAO-UHFFFAOYSA-N 0.000 description 1
- UANSQQFYKHHDJM-KRWDZBQOSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]naphthalene-1-carboxamide Chemical compound C1=CC=C2C(C(N[C@@H]3C4CCN(CC4)C3)=O)=CC=CC2=C1 UANSQQFYKHHDJM-KRWDZBQOSA-N 0.000 description 1
- LBJXTLRJYSTBQL-UHFFFAOYSA-N n-[(5-bromothiophen-2-yl)methyl]-2,4,5-trifluoroaniline Chemical compound C1=C(F)C(F)=CC(F)=C1NCC1=CC=C(Br)S1 LBJXTLRJYSTBQL-UHFFFAOYSA-N 0.000 description 1
- IPTXQVOUOJMRAU-UHFFFAOYSA-N n-[2-(3,4-dimethoxyphenyl)ethyl]-n-[(5-methylfuran-2-yl)methyl]carbamoyl chloride Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C(Cl)=O)CC1=CC=C(C)O1 IPTXQVOUOJMRAU-UHFFFAOYSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- KVNPRHJSNCFLEG-UHFFFAOYSA-N n-benzyl-n-phenylcarbamoyl chloride Chemical compound C=1C=CC=CC=1N(C(=O)Cl)CC1=CC=CC=C1 KVNPRHJSNCFLEG-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- JVKPGXHNRQRNEO-UHFFFAOYSA-N n-butyl-n-phenylcarbamoyl chloride Chemical compound CCCCN(C(Cl)=O)C1=CC=CC=C1 JVKPGXHNRQRNEO-UHFFFAOYSA-N 0.000 description 1
- VSHTWPWTCXQLQN-UHFFFAOYSA-N n-butylaniline Chemical compound CCCCNC1=CC=CC=C1 VSHTWPWTCXQLQN-UHFFFAOYSA-N 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 208000005346 nocturnal enuresis Diseases 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- VNZRXVSSZGTIET-UHFFFAOYSA-N pent-4-enyl(phenyl)carbamic acid Chemical compound C=CCCCN(C(=O)O)C1=CC=CC=C1 VNZRXVSSZGTIET-UHFFFAOYSA-N 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- UIMCAHUVQVVYPJ-UHFFFAOYSA-N pentyl(phenyl)carbamic acid Chemical compound CCCCCN(C(O)=O)C1=CC=CC=C1 UIMCAHUVQVVYPJ-UHFFFAOYSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 229920000075 poly(4-vinylpyridine) Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- XIIOFHFUYBLOLW-UHFFFAOYSA-N selpercatinib Chemical compound OC(COC=1C=C(C=2N(C=1)N=CC=2C#N)C=1C=NC(=CC=1)N1CC2N(C(C1)C2)CC=1C=NC(=CC=1)OC)(C)C XIIOFHFUYBLOLW-UHFFFAOYSA-N 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 230000016160 smooth muscle contraction Effects 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000005415 substituted alkoxy group Chemical group 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 230000016978 synaptic transmission, cholinergic Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- UGNBYYMFTQXRAI-UHFFFAOYSA-N thiophen-3-ylmethylcarbamic acid Chemical compound OC(=O)NCC=1C=CSC=1 UGNBYYMFTQXRAI-UHFFFAOYSA-N 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 208000022934 urinary frequency Diseases 0.000 description 1
- 230000036318 urination frequency Effects 0.000 description 1
- 230000001515 vagal effect Effects 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Otolaryngology (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200201439A ES2203327B1 (es) | 2002-06-21 | 2002-06-21 | Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen. |
| PCT/EP2003/006472 WO2004000840A2 (en) | 2002-06-21 | 2003-06-18 | Quinuclidine derivatives and pharmaceutical compositions containing the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA04012272A true MXPA04012272A (es) | 2005-04-08 |
Family
ID=29797397
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA04012272A MXPA04012272A (es) | 2002-06-21 | 2003-06-18 | Nuevos derivados de quinuclidina y composiciones medicinales que contienen los mismos. |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US7435742B2 (https=) |
| EP (1) | EP1515968A2 (https=) |
| JP (1) | JP2005533799A (https=) |
| CN (1) | CN100363363C (https=) |
| AR (1) | AR040275A1 (https=) |
| AU (1) | AU2003279384A1 (https=) |
| BR (1) | BR0312169A (https=) |
| CA (1) | CA2490082A1 (https=) |
| EC (1) | ECSP045484A (https=) |
| ES (1) | ES2203327B1 (https=) |
| IL (1) | IL165775A0 (https=) |
| MX (1) | MXPA04012272A (https=) |
| NO (1) | NO20050217L (https=) |
| NZ (1) | NZ537252A (https=) |
| PE (1) | PE20040579A1 (https=) |
| RU (1) | RU2321588C2 (https=) |
| TW (1) | TW200401776A (https=) |
| UA (1) | UA85541C2 (https=) |
| UY (1) | UY27850A1 (https=) |
| WO (1) | WO2004000840A2 (https=) |
| ZA (1) | ZA200410211B (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ526580A (en) | 2000-12-22 | 2005-04-29 | Almirall Prodesfarma Ag | Quinuclidine carbamate derivatives and their use as M3 antagonists |
| ES2203327B1 (es) | 2002-06-21 | 2005-06-16 | Almirall Prodesfarma, S.A. | Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen. |
| ES2204295B1 (es) | 2002-07-02 | 2005-08-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de quinuclidina-amida. |
| US7056916B2 (en) | 2002-11-15 | 2006-06-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Medicaments for the treatment of chronic obstructive pulmonary disease |
| DK2422786T3 (da) * | 2004-04-22 | 2014-11-17 | Boehringer Ingelheim Int | Nye lægemiddelkombinationer til behandling af luftvejssygdomme |
| US20080287487A1 (en) * | 2004-06-30 | 2008-11-20 | Anthony William James Cooper | Muscarinic Acetylcholine Receptor Antagonists |
| ES2246170B1 (es) * | 2004-07-29 | 2007-04-01 | Almirall Prodesfarma, S.A. | Nuevo procedimiento para preparar derivados de carbamato de quinuclidinio. |
| GB0424284D0 (en) | 2004-11-02 | 2004-12-01 | Novartis Ag | Organic compounds |
| BRPI0614410A2 (pt) | 2005-08-15 | 2011-03-29 | Boehringer Ingelheim Int | processo para preparação de betamiméticos |
| DE102006028286A1 (de) * | 2006-06-20 | 2007-12-27 | Wirsich, Konrad, Dipl.-Ing. (FH) | Drehmoment- und rutschfest verbundene aus zwei Teilen bestehende Schaltzahnräder |
| EP1882691A1 (en) * | 2006-07-26 | 2008-01-30 | CHIESI FARMACEUTICI S.p.A. | Quinuclidine derivatives as M3 antagonists |
| EP2119716A4 (en) * | 2007-02-09 | 2011-06-01 | Astellas Pharma Inc | AZA BRIDGE CYCLE COMPOUND |
| CA2675942C (en) * | 2007-02-23 | 2016-04-12 | Theravance, Inc. | Quaternary ammonium diphenylmethyl compounds useful as muscarinic receptor antagonists |
| EP2065385A1 (en) | 2007-11-28 | 2009-06-03 | Laboratorios SALVAT, S.A. | Stable crystalline salt of (R)-3-fluorophenyl-3,4,5-trifluorobenzylcarbamic acid 1-azabiciyclo [2.2.2]oct-3-yl ester |
| EP2080507A1 (en) * | 2008-01-15 | 2009-07-22 | CHIESI FARMACEUTICI S.p.A. | Pharmaceutical formulations comprising an anticholinergic drug |
| WO2011094434A2 (en) * | 2010-01-28 | 2011-08-04 | Theron Pharmaceuticals, Inc. | 7-azoniabicyclo [2.2.1] heptane derivatives, methods of production, and pharmaceutical uses thereof |
| KR101987736B1 (ko) * | 2011-03-18 | 2019-06-11 | 젠자임 코포레이션 | 글루코실세라마이드 합성효소 억제제 |
| EP2631674A1 (de) * | 2012-02-23 | 2013-08-28 | ELMOS Semiconductor AG | Verfahren und Sensorsystem zur Vermessung der Eigenschaften einer Übertragungsstrecke eines Messsystems zwischen Sender und Empfänger |
| MA37975B2 (fr) | 2012-09-11 | 2021-03-31 | Genzyme Corp | Inhibiteurs de synthase de glucosylcéramide |
| JP6218940B2 (ja) * | 2013-07-13 | 2017-10-25 | ベイジン エフエスウェルカム テクノロジー ディベロップメント カンパニー リミテッド | キニン系化合物、その光学異性体及びその製造方法と医薬用途 |
| US10570127B1 (en) | 2018-11-05 | 2020-02-25 | Renexxion, Llc | Material and methods for the treatment of gastro-intestinal disorders |
| CN114040762A (zh) | 2019-02-04 | 2022-02-11 | 建新公司 | 使用葡糖神经酰胺合酶(gcs)的抑制剂治疗纤毛疾病 |
| JP2023512366A (ja) | 2020-02-03 | 2023-03-27 | ジェンザイム・コーポレーション | リソソーム蓄積性疾患と関連する神経学的症状を処置するための方法 |
| CN115605202B (zh) | 2020-03-26 | 2025-10-28 | 盐野义制药株式会社 | 具有血清素受体结合活性的芳香族杂环衍生物 |
| AU2021311131B2 (en) | 2020-07-24 | 2026-02-19 | Genzyme Corporation | Pharmaceutical compositions comprising venglustat |
| US20240083872A1 (en) * | 2020-12-28 | 2024-03-14 | Shionogi & Co., Ltd. | Cyclic amine derivatives having serotonin receptor binding activity |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2762796A (en) * | 1956-09-11 | Iminodibenzyl derivative | ||
| GB1219606A (en) | 1968-07-15 | 1971-01-20 | Rech S Et D Applic Scient Soge | Quinuclidinol derivatives and preparation thereof |
| GB1246606A (en) | 1969-04-28 | 1971-09-15 | Starogardzkie Zakl Farma | Dibenzo-azepine derivatives |
| GB8825505D0 (en) * | 1988-11-01 | 1988-12-07 | Pfizer Ltd | Therapeutic agents |
| GB8923590D0 (en) | 1989-10-19 | 1989-12-06 | Pfizer Ltd | Antimuscarinic bronchodilators |
| GB9201751D0 (en) | 1992-01-28 | 1992-03-11 | Smithkline Beecham Plc | Compounds |
| GB9202443D0 (en) | 1992-02-05 | 1992-03-18 | Fujisawa Pharmaceutical Co | A novel substituted-acetamide compound and a process for the preparation thereof |
| WO1995006635A1 (en) * | 1993-09-02 | 1995-03-09 | Yamanouchi Pharmaceutical Co., Ltd. | Carbamate derivative and medicine containing the same |
| AU685225B2 (en) | 1994-02-10 | 1998-01-15 | Yamanouchi Pharmaceutical Co., Ltd. | Novel carbamate derivative and medicinal composition containing the same |
| NO2005012I1 (no) | 1994-12-28 | 2005-06-06 | Debio Rech Pharma Sa | Triptorelin og farmasoytisk akseptable salter derav |
| ATE205490T1 (de) | 1995-10-13 | 2001-09-15 | Banyu Pharma Co Ltd | Substituierte heteroaromatische derivate |
| AUPN862996A0 (en) | 1996-03-13 | 1996-04-04 | Fujisawa Pharmaceutical Co., Ltd. | A novel substituted-acetamide compound |
| PE92198A1 (es) * | 1996-08-01 | 1999-01-09 | Banyu Pharma Co Ltd | Derivados de 1,4-piperidina disustituida que contienen fluor |
| ES2165768B1 (es) * | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| KR100751981B1 (ko) * | 2000-06-27 | 2007-08-28 | 라보라토리오스 살바트, 에스.에이. | 아릴알킬아민으로부터 유도된 카바메이트 |
| NZ526580A (en) * | 2000-12-22 | 2005-04-29 | Almirall Prodesfarma Ag | Quinuclidine carbamate derivatives and their use as M3 antagonists |
| DE60121813T2 (de) | 2000-12-28 | 2007-09-20 | Almirall Ag | Neue chinuclidinderivate und medizinische zusammensetzungen, die diese verbindungen enthalten |
| JP4505227B2 (ja) | 2001-12-20 | 2010-07-21 | キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ | １−アルキル−１−アゾニアビシクロ［２．２．２］オクタンカルバメート誘導体およびムスカリンレセプターアンタゴニストとしてのそれらの使用 |
| ES2203327B1 (es) | 2002-06-21 | 2005-06-16 | Almirall Prodesfarma, S.A. | Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen. |
| ES2204295B1 (es) | 2002-07-02 | 2005-08-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de quinuclidina-amida. |
-
2002
- 2002-06-21 ES ES200201439A patent/ES2203327B1/es not_active Expired - Fee Related
-
2003
- 2003-06-16 UY UY27850A patent/UY27850A1/es not_active Application Discontinuation
- 2003-06-18 WO PCT/EP2003/006472 patent/WO2004000840A2/en not_active Ceased
- 2003-06-18 EP EP03740284A patent/EP1515968A2/en not_active Withdrawn
- 2003-06-18 CN CNB038193272A patent/CN100363363C/zh not_active Expired - Fee Related
- 2003-06-18 CA CA002490082A patent/CA2490082A1/en not_active Abandoned
- 2003-06-18 UA UAA200500504A patent/UA85541C2/ru unknown
- 2003-06-18 BR BR0312169-0A patent/BR0312169A/pt not_active IP Right Cessation
- 2003-06-18 US US10/518,496 patent/US7435742B2/en not_active Expired - Fee Related
- 2003-06-18 MX MXPA04012272A patent/MXPA04012272A/es not_active Application Discontinuation
- 2003-06-18 NZ NZ537252A patent/NZ537252A/en unknown
- 2003-06-18 RU RU2005101409/04A patent/RU2321588C2/ru not_active IP Right Cessation
- 2003-06-18 JP JP2004514785A patent/JP2005533799A/ja active Pending
- 2003-06-18 PE PE2003000615A patent/PE20040579A1/es not_active Application Discontinuation
- 2003-06-18 AU AU2003279384A patent/AU2003279384A1/en not_active Abandoned
- 2003-06-19 AR ARP030102175A patent/AR040275A1/es unknown
- 2003-06-20 TW TW092116832A patent/TW200401776A/zh unknown
-
2004
- 2004-12-10 EC EC2004005484A patent/ECSP045484A/es unknown
- 2004-12-15 IL IL16577504A patent/IL165775A0/xx unknown
- 2004-12-17 ZA ZA200410211A patent/ZA200410211B/xx unknown
-
2005
- 2005-01-13 NO NO20050217A patent/NO20050217L/no not_active Application Discontinuation
-
2008
- 2008-09-05 US US12/205,334 patent/US20090054480A1/en not_active Abandoned
- 2008-09-05 US US12/205,315 patent/US20090005412A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| RU2321588C2 (ru) | 2008-04-10 |
| CN1675206A (zh) | 2005-09-28 |
| CN100363363C (zh) | 2008-01-23 |
| NO20050217L (no) | 2005-03-18 |
| EP1515968A2 (en) | 2005-03-23 |
| US7435742B2 (en) | 2008-10-14 |
| RU2005101409A (ru) | 2005-11-20 |
| JP2005533799A (ja) | 2005-11-10 |
| UA85541C2 (ru) | 2009-02-10 |
| AU2003279384A1 (en) | 2004-01-06 |
| ES2203327B1 (es) | 2005-06-16 |
| US20090005412A1 (en) | 2009-01-01 |
| PE20040579A1 (es) | 2004-09-08 |
| BR0312169A (pt) | 2005-03-29 |
| WO2004000840A3 (en) | 2004-02-19 |
| IL165775A0 (en) | 2006-01-15 |
| ZA200410211B (en) | 2005-09-06 |
| ECSP045484A (es) | 2005-01-28 |
| CA2490082A1 (en) | 2003-12-31 |
| TW200401776A (en) | 2004-02-01 |
| AR040275A1 (es) | 2005-03-23 |
| ES2203327A1 (es) | 2004-04-01 |
| WO2004000840A2 (en) | 2003-12-31 |
| US20090054480A1 (en) | 2009-02-26 |
| UY27850A1 (es) | 2003-11-28 |
| NZ537252A (en) | 2006-07-28 |
| US20060094751A1 (en) | 2006-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1345937B1 (en) | Quinuclidine carbamate derivatives and their use as m3 antagonists | |
| US20090054480A1 (en) | Novel quinuclidine carbamate derivatives and medicinal compositions containing the same | |
| US7718670B2 (en) | Quinuclidine amide derivatives | |
| US7879874B2 (en) | Quinuclidine derivatives and medicinal compositions containing the same | |
| AU2002228015A1 (en) | Quinuclidine carbamate derivatives and their use as M3 antagonists | |
| HK1055120B (en) | Quinuclidine carbamate derivatives and their use as m3 antagonists | |
| KR20050024366A (ko) | 퀴누클리딘 유도체 및 이를 함유하는 약학 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HC | Change of company name or juridical status |
Owner name: RAUMEDIC AG |
|
| GB | Transfer or rights |
Owner name: LABORATORIOS ALMIRALL, S.A. |
|
| FA | Abandonment or withdrawal |